New pill could help kidneys last longer

NCT ID NCT07419828

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether HRS-1780 tablets can slow the decline of kidney function in nearly 2,000 adults with chronic kidney disease. Participants take the drug or a placebo alongside standard treatment. The study will track kidney health over 32 months to see if the drug helps preserve kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HRS-1780 tablets
What this could lead to
If successful, HRS-1780 could offer a new way to slow kidney function loss in people with chronic kidney disease, potentially delaying the need for dialysis or transplant.
What could go wrong
This is a large Phase 3 trial, but the drug is still experimental. It may not prove better than standard care, and side effects are possible. Results are not expected for over two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

    RECRUITING

    Nanjing, Jiangsu, 210002, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.